Elanco Animal Health Incorporated
NYSEELAN short interest surges 25% in one week to 6.5% of float, driven by a massive jump in shares on loan as the stock rallies 4% and CEO buys the dip.
Snapshot as of 22 Jun 2026
Elanco Animal Health heads into the first week of June with a striking contradiction: short sellers have rebuilt positions aggressively while the company's own CEO put fresh money to work at the lows. Short interest…
Elanco Animal Health reports Q1 2026 results today against a backdrop of unusual insider conviction — the CEO buying shares at current prices just days before the earnings release. On May 15, CEO Jeff Simmons purchased…
Elanco Animal Health heads into its May 8 earnings with a striking divergence: the stock is up 20% on the week while the broader pharmaceutical peer group has crumbled. The price move alone commands attention. Elanco…
ELAN reported Q1 2026 results on May 6 that landed well ahead of consensus, and the stock's response has put short sellers firmly on the back foot. Adjusted EPS came in at $0.40 against a $0.35 estimate. Sales hit…
Elanco Animal Health reports Q1 2026 results on May 6 with the Street broadly constructive — but the stock has spent the past month drifting lower, testing how much of that optimism is already in the price. The analyst…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for ELAN — free to start on ORTEX.
Sign up for free →Open ELAN on ORTEX